Status:
COMPLETED
To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients
Lead Sponsor:
Novartis
Conditions:
Alzheimer Disease
Eligibility:
All Genders
40-85 years
Phase:
PHASE2
Brief Summary
This study will evaluate the safety and tolerability of repeated subcutaneous injections of CAD106 in patients with Alzheimer's disease.
Eligibility Criteria
Inclusion
- Patients who have completed the Core study with no significant safety concerns
Exclusion
- Diagnosis of other neurodegenerative disease and/or psychiatric disorders (with the exception of successfully treated depression).
- Diagnosis or presence of an active, uncontrolled seizure disorder and/or cerebrovascular disease.
- diagnosis or presence of an active autoimmune and/or with an acute or chronic inflammation.
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT00956410
Start Date
September 1 2009
End Date
June 1 2011
Last Update
February 11 2020
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Bordeaux, France
2
Novartis Investigative Site
Stockholm, Sweden
3
Novartis Investigative Site
Basel, Switzerland
4
Novartis Investigative Site
Southampton, United Kingdom